A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

Aussies have been warned to think before they jab, with more counterfeit Ozempic-labelled products seized at the border.

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...